Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
653 Investment Partners is a private investment firm. Its website positions it as a private investment company “by entrepreneurs for entrepreneurs,” with a focus on healthcare, technology, veterinary health, and real estate projects. It is worth noting that although it may fall under the broader payments/finance category, the crawled content suggests it is not a payment gateway, acquiring institution, wallet, or fintech infrastructure provider. Instead, it is closer to a private equity / growth investment platform.
Its main selling point is the industry track record of its three Principal Partners. Team members have founded, operated, and sold multiple specialty pharmacy, pharmacy technology, pharmaceutical, and healthcare-related companies, with examples including AcariaHealth, CuraScript, Three Rivers Pharmaceuticals, and Creehan & Company. The website emphasizes that it provides portfolio companies with additional investment, experience, ideas, and integrity-driven support, helping businesses scale, deliver value, and realize their potential. Its investment preferences include teams with clear customer value, healthcare companies that simplify the complexity of medical care, technology-enabled businesses, pet health businesses, and real estate projects that create value through repurposing, filling market gaps, and similar approaches.
The website does not disclose fund size, individual investment amounts, investment stages, equity requirements, management fees, carried interest, or investor eligibility criteria. It also does not provide information on settlement, payment methods, or payout timelines. Therefore, companies seeking funding would need to contact the firm via its form or email and submit materials for further evaluation by its team.
The main advantage is the team’s strong industry experience, especially in U.S. specialty pharmacy, PBM, healthcare technology, and pharmacy software, where they have hands-on experience founding companies and achieving exits. This may allow them to provide more in-depth strategic and operational support than capital alone. The downside is limited public transparency: the website does not provide a full portfolio, historical returns, compliance registrations, licenses, or details on its due diligence process. For users looking for payments or financial infrastructure, it also does not offer capabilities such as payments, risk control, or API integration.
653 Investment Partners is better suited to entrepreneurs in healthcare, pharmacy technology, veterinary health, technology-driven businesses, and real estate projects who are seeking capital and industry resources. The source text does not provide information on access from mainland China, so this is considered unknown.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on 653investments.com official site.
653investments.com is an United States Accelerators & VC provider. TG4G tracks its product information, an overall rating of 5.0/10, and a China-accessibility score of Limited (proxy recommended). Click "Visit Official Site" to reach 653investments.com directly.